OncLive argues the Breast Cancer Index test can guide shared decisions on how long to continue extended adjuvant endocrine therapy in early-stage HR-positive breast cancer, aiming to balance recurrence risk against side effects.
Dr Diab on the Clinical Relevance of the Breast Cancer Index in HR+ Early-Stage Disease.
foundational tool for guiding shared decision-making
duration of extended adjuvant hormonal therapy
Clinical Relevance of the Breast Cancer Index in HR+ Early-Stage Disease
clinical utility of the Breast Cancer Index (BCI) test
guiding shared decision-making regarding the duration of extended adjuvant hormonal therapy
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare